Katharina Buczek
“There is a huge need for diversity in clinical research, not just by skin color but also by socioeconomic background,” Karikari said.
“To develop better drugs, trials need to enroll people from varied backgrounds and not just those who live close to academic medical centers. A blood test is cheaper, safer, and easier to administer, and it can improve clinical confidence in diagnosing Alzheimer’s and selecting participants for clinical trial and disease monitoring.”
The researchers’ next steps include the launch of a large-scale effort to clinically validate blood BD-tau among a wide range of research groups, which recruit participants from memory clinics, the community, and diverse ethnic and racial backgrounds. The studies will also include older adults with no biological evidence of AD, in addition to patients at different stages of AD.
These steps are critical for ensuring that the biomarker results are applicable to patients from all backgrounds. Moreover, they are vital for making BD-tau a commercially available option for clinical use.
To read the study’s complete findings, which have since been published in Oxford Academic, visit the link here.
If true crime defines your free time, this is for you: join Chip Chick’s True Crime Tribe
Researchers Discovered That Etching Grooves Onto N95 Facemasks Helps Prevent The Spread Of Disease
Brownie Truffle Balls Are One Of Her Favorite Recipes To Serve At A Party
